Form 4: Teva Director Mignone Acquires Restricted Share Units

Roberto Mignone, a Director at Teva Pharmaceutical Industries Ltd., acquired 7,242 restricted share units on May 28, 2026, as part of his compensation.

Summary

• Roberto Mignone, a Director at Teva Pharmaceutical Industries Ltd., acquired 7,242 restricted share units (RSUs) on May 28, 2026.
• These RSUs represent a contingent right to receive one ordinary share or its cash equivalent upon settlement.
• The RSUs are scheduled to vest on May 28, 2027.
• The transaction was reported on June 1, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard equity grant to a director rather than a significant new investment or divestment.

Positives

• Director acquisition of equity signals confidence in the company's future prospects.
• The grant of restricted share units is a common form of executive and director compensation, aligning incentives with long-term shareholder value.

Future Outlook

The restricted share units granted to Roberto Mignone vest on May 28, 2027, indicating a forward-looking incentive tied to continued service and company performance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the acquisition of equity by directors, are common within the pharmaceutical industry as a method to retain talent and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of RSUs by a director can be viewed positively as it aligns management incentives with long-term shareholder value.
• Employees: This transaction is part of the company's compensation strategy for its directors, which may influence broader compensation practices.
• Management: Roberto Mignone benefits from the equity grant, contingent on future vesting.

Next Steps

• Vesting of 7,242 restricted share units on May 28, 2027.
• Potential settlement of RSUs into ordinary shares or cash equivalent at the discretion of the Human Resources and Compensation Committee.

Key Dates

Keywords

Teva Pharmaceutical Industries, Form 4, Director, Restricted Share Units, Equity Award, Insider Transaction, TEVA